title: Canagliflozin: a new option for managing diabetes.
abstract: Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic infections.
authors.affiliation: At the time this article was written, Molly Livingston was a student in the doctor of pharmacy program at Presbyterian College School of Pharmacy in Clinton, S.C. Jennifer N. Clements is an associate professor in the Department of Pharmacy Practice at Presbyterian College School of Pharmacy.
authors.forename: Molly
authors.initials: M
authors.lastname: Livingston
authors.forename: Jennifer N
authors.initials: JN
authors.lastname: Clements
mesh_terms: D000068896:Canagliflozin / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D000068896:Canagliflozin